Global Kaposi's Sarcoma Market Accelerates with Rising HIV/AIDS Prevalence and Innovative Treatments

The global Kaposi’s Sarcoma market is expanding due to the HIV/AIDS prevalence, improved oncology infrastructure, and advancements in targeted and immunotherapeutic drugs. Kaposi’s Sarcoma, a tumor ...
Monitor

The importance of viral suppression in preventing cancer

Living with HIV comes with unique health challenges, but advances in treatment have transformed it into a manageable chronic ...

Why Common Cold Symptoms Can Vary A Lot Among Different People

Who knows why different people have different symptoms with the common cold? Well, a new study used laboratory-grown noses ...
BioPharma Dive

Sanofi to seek approval of touted eczema drug despite mixed results

Fresh data from multiple studies suggest the drug, which Sanofi has billed as a future blockbuster, could be cleared in the U ...
Fierce Biotech

Sanofi plans global filings for key eczema prospect despite mixed phase 3 readout

Sanofi has reported mixed phase 3 data on amlitelimab, further muddying the prospec | Sanofi has reported mixed phase 3 data ...

AIDS took Ross Laycock 35 years ago. His legacy lives on

Opinion: Artist Carl George remembers his late friend Ross Laycock, whose life and love story with Felix Gonzalez-Torres left ...

Press Release: Sanofi's amlitelimab confirms its potential in atopic dermatitis

Sanofi's amlitelimab confirms its potential in atopic dermatitisIn the SHORE phase 3 study, amlitelimab in combination with topical therapies met ...
Medical Dialogues

Amlitelimab Shows Promise in Moderate-to-Severe Atopic Dermatitis in Phase 3 trial

Amlitelimab, an OX40 ligand–targeting therapy that modulates T-cell-mediated inflammation without causing cell depletion, ...
Pharmabiz

Sanofi's amlitelimab confirms its potential in atopic dermatitis

Sanofi's amlitelimab confirms its potential in atopic dermatitis: Paris Saturday, January 24, 2026, 10:00 Hrs [IST] Following the positive COAST 1 (clinical study identifier: NCT0 ...